Patents Examined by Sergio Coffa
  • Acylated oxyntomodulin peptide analog
    Patent number: 11236142
    Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Assignee: DONG-A ST CO., LTD.
    Inventors: Jae-Sung Yang, Kyung-Seok Lee, Yu-Na Chae, Gye-Rim Baek, Tae-Hyoung Kim, Ill-Hun Jung, Chae-Lim Ryu, Weon-Bin Im
  • Defined three dimensional microenvironment for cell culture
    Patent number: 11220669
    Abstract: Described is a three-dimensional (3D) microenvironment presenting defined biochemical and physical cues that regulate cellular behavior and use of the microenvironment. A composition to form the 3D microenvironment is provided by combining one or more natural or synthetic polymeric materials and substrate proteins recombinantly or chemically functionalized with a variety of bioactive peptides such as extracellular matrix-derived or growth factor-derived peptides. Also described are devices and methods for screening for optimal combinations of the bioactive motifs in order to create an extracellular microenvironment that can regulate specific cellular behavior such as cell growth, proliferation, migration or differentiation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 11, 2022
    Assignees: Amolifescience Co., Ltd., Kollodis BioSciences, Inc.
    Inventors: Chan Kim, Kyuwon Baek, Hui-Gwan Goo, Sangjae Lee, Bongjin Hong, Song Hee Koo, In Yong Seo, Seung Hoon Lee, Ji Hyun Lee, Seonho Jang, Dong-Sik Seo
  • Method for thioether conjugation of proteins
    Patent number: 11219690
    Abstract: The invention relates to methods for obtaining a protein conjugate wherein a cysteine residue of the protein serves as attachment point for the chemical moiety conjugated to the protein.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Charlotte Schou Hunneche, Thomas Budde Hansen, Ernst Broberg Hansen
  • Anti-KRAS-T cell receptors
    Patent number: 11208456
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: December 28, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Peptide for cytosolic delivery
    Patent number: 11179471
    Abstract: Provided is a peptide represented by the following formula (I): R1-IWLTALX5FLGX6X1AAX7X2X3AX8QX4LSX9L-R2?(I) wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, R1, and R2 are as defined in the specification.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: November 23, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Shiroh Futaki, Kentarou Sakamoto, Misao Akishiba
  • Peptides and compositions for prevention of cell adhesion and methods of using same
    Patent number: 11174299
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence consisting of SVHSFDYDWYNV, or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: November 16, 2021
    Assignee: DISPERSEBIO LTD.
    Inventor: Amir Zlotkin
  • Peptide and use thereof
    Patent number: 11168113
    Abstract: (Technical problems to be solved) Providing a method for selecting an mineral of molybdenum. (Means for solving the problems) A peptide comprising an amino acids sequence according the following formula (1) and/or (2): (1) (ALRKNMD-FCPQSETGWHYIV)-(LIVFA)-(HPWRK)-(TSNQ)-(TSNQ)-(LIVFA)-(TSNQ)-(TSNQ)-(LIVFA)-(FYW)-(LIVFA)-(HPWRK) (2) (LIVFA)-(RHK)-(TSNQ)-(LIVFA)-(LIVFA)-(TSNQ)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(RHK)-(HPW) wherein one amino acid is respectively selected from each group defined by paired parentheses.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 9, 2021
    Assignees: SHIBAURA INSTITUTE OF TECHNOLOGY, JX NIPPON MINING & METALS CORPORATION
    Inventors: Mitsuo Yamashita, Akira Miura
  • Antiviral peptide and use thereof
    Patent number: 11155582
    Abstract: An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 26, 2021
    Assignees: TOAGOSEI CO., LTD, National University Corporation Hokkaido University
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Hot flash-suppressing agent
    Patent number: 11147856
    Abstract: The present invention relates to hot flash-suppressing agents and menopausal disorder-improving agents and a food and drink and a pharmaceutical preparation for suppressing hot flash, containing ?-lactalbumin as an active ingredient.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 19, 2021
    Assignee: MEIJI CO., LTD.
    Inventors: Masayuki Uchida, Orie Kobayashi
  • Method for the treatment or prevention of osteoarthritis
    Patent number: 11141461
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 12, 2021
    Assignee: Chondropeptix
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Antimicrobial peptide and its use thereof
    Patent number: 11142562
    Abstract: The present invention relates to a novel peptide that exhibits effective antimicrobial activity against various gram-positive and gram-negative bacteria that are involved in food-borne pathogenesis, food spoilage and other pathogenic conditions. Therefore, this peptide can be a good candidate as antibacterial in agricultural, food and beverage industry, as well as for other medical applications and societal use.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 12, 2021
    Assignee: Council of Scientific & Industrial Research
    Inventors: Balaji Prakash, Yashavanth Linganamane, Abhishek Acharya
  • Method for the treatment or prevention of osteoarthritis
    Patent number: 11141462
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: October 12, 2021
    Assignee: Chondropeptix B.V.
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • CD40 targeted peptides and uses thereof
    Patent number: 11130783
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 28, 2021
    Assignees: Regents of the University of Minnesota, Diabetes-Free, Inc.
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath
  • Rapid-acting insulin compositions
    Patent number: 11123406
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
    Patent number: 11091515
    Abstract: The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, the prevention and alleviation of arteriosclerosis or cardiovascular diseases, and the prevention and alleviation of heart failure.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 17, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Hyo Soo Kim, Hyun Duk Jang, Sang Eun Lee
  • Methods and compositions for treating mucosal tissue disorders
    Patent number: 11058743
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: July 13, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Peptides and methods for preventing ischemic tissue injury
    Patent number: 11033607
    Abstract: Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: June 15, 2021
    Assignee: University Health Network
    Inventors: Mansoor Husain, Dhanwantee Mundil
  • Peptides for binding epidermal growth factor
    Patent number: 11034728
    Abstract: A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 15, 2021
    Assignee: 3M Innovative Properties Company
    Inventors: Minghua Dai, Amy K. McNulty, Federica Sgolastra, Jie Liu, Jana Ninkovic, Robert T. Fitzsimons, Jr.
  • Non-antibody binding proteins binding to PD-1 receptors and uses thereof
    Patent number: 11014974
    Abstract: Provided is a non-antibody binding protein binding to PD-1 receptor which has a sequence as shown in SEQ ID NO:1 and its analogues. Also provided is use of the non-antibody binding protein in the preparation of a formulation for treating PD-1 pathway related diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 25, 2021
    Assignees: ORAL SUBSIDIARY SUN YAT-SEN UNIVERSITY HOSPITAL, GUANGZHOU YIDAI PHARMACEUTICAL CO., LTD.
    Inventors: Hua Wang, Xiaofeng Huang, Long Zhao, Yan Zhang
  • Peptidomimetic macrocycles
    Patent number: 11008366
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: May 18, 2021
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Vincent Guerlavais, Noriyuki Kawahata